Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA CertaraDecember 11, 2024
Optimizing Clinical Development: Saving Time and Costs Case Study Optimizing Clinical Development: Saving Time and Costs Strategic mechanistic modeling solutions help an immunoncology biotech accelerate their clinical development of novel therapeutics.CertaraAugust 16, 2024
Systems Modeling Delivers Efficiencies and Savings in Clinical Development Case Study Systems Modeling Delivers Efficiencies and Savings in Clinical Development Discover how an IO-focused company developing immunotherapies applied QSP modeling solutions for cost-effective clinical development.…CertaraJuly 12, 2024
Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm Publication Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit…CertaraJuly 26, 2020